U.S. Senate narrowly confirms Dr. Robert Califf to lead FDA for second time – Reuters

• Respected FDA GMP online training courses and programs by SkillsPlus International Inc.

U.S. Senate narrowly confirms Dr. Robert Califf to lead FDA for second time – Reuters

Welcome Back, Commissioner Califf! Robert M. Califf, M.D., was sworn in as the Commissioner of Food and Drugs on February 17, 2022. – FDA.gov

Obama's Pick to Lead FDA Nears Senate Confirmation - Scientific American

Read the full article: Obama's Pick to Lead FDA Nears Senate Confirmation - Scientific American:

"After a five-month delay, the US Senate is finally poised to vote on the nominee to head the US Food and Drug Administration (FDA), cardiologist and clinical trials expert Robert Califf.

On February 22, lawmakers voted to limit debate on Califf's nomination. That procedural tactic sets the stage for a final vote this week that would determine whether he will lead the FDA."

'via Blog this'

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

If you are looking for live, onsite, in-person delivered courses or classes, then consider the following popular courses:

Our most popular course

Put fun back into GMP training!

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

Global Outsourcing - Clinical Drug Trials - Hot Debate

Global outsourcing continues, and fuels some interesting debate, as evidenced by this recent New England Journal of Medicine (NEJM) article, "Ethical and Scientific Implications of the Globalization of Clinical Research." Of current interest, one of the author's name, Robert Califf, comes up as a candidate to lead the FDA. In CenterWatch's Clinicial Trials Today post, "Duke, NEJM Study Renews Debate on Global Outsourcing, they say "the NEJM study findings support common criticisms that trial participants in developing countries are often less informed and unduly influenced by the promise of money or medical care in return for participating in a study. While critics of clinical research in emerging areas (comprising 16% of total global clinical trials) can deride the informed consent process there, the West is no stranger to these problems." 

Related Posts: FDA Draft Guidance - Drug Supply Chain and SNIs FDA - Global Drug Supply Chain Needs Better Oversight Prescription Drug Reimportation and Safety - Both Presidential Candidates Support It 

Return Home: http://drughealth.blogspot.com/